|
BOARD OF DIRECTORS
Robin L. Smith, M.D., MBA
Chief Executive Officer and Chairman of the Board
Dr. Robin L. Smith joined the Company as Chairman of its Advisory Board in September 2005 and, effective June 2, 2006, became the Chief Executive Officer and Chairman of the Board. Dr. Smith, who received a medical degree from Yale University in 1992 and a master's degree in business administration from the Wharton School in 1997, brings to the Company extensive experience in medical enterprises and business development. From 2000 to 2003, Dr. Smith served as President & Chief Executive Officer of IP2M, a multi-platform media company specializing in healthcare. During her term, the company was selected as being one of the 10 fastest growing technology companies in Houston. IP2M was sold to a publicly-traded company in February 2003. Previously, from 1998 to 2000, she was Executive Vice President and Chief Medical Officer for HealthHelp, Inc., a National Radiology Management company that managed 14 percent of the healthcare dollars spent by large insurance companies.
Dr. Smith has acted as a senior advisor and investor to both publicly traded and privately held companies including but not limited to China Biopharmaceutical Holdings, Phase III Medical (the Company's predecessor), the Madelin Fund, HC Innovations Inc., Navstar Media Holdings, Strike Force, Health Quest, Red Lion Partners and All American Pet, where she has played a significant role in restructuring and or growing the companies. Dr. Smith served on the Board of Directors of two privately held companies, Talon Air and Biomega, and also served on the Chemotherapy Foundation Board of Trustees and The New York Theatre Ballet. She currently serves on the Board of Trustees of the NYU Medical Center Board, is Chairman of the Board of Directors for the New York University Hospital for Joint Diseases where she heads up new development efforts and board member recruitment, and serves on the Board of Choose Living. Dr. Smith is the President and serves on the Board of Directors of The Stem for Life Foundation.
Dr. Smith was originally appointed to the Board of Directors in June 2006 pursuant to the terms of the Securities Purchase Agreement in the June 2006 private placement.
Richard Berman, Director
Richard Berman joined the Board of Directors of the Company in November 2006, serves as Chairman of the Compensation Committee and Chairman of the Audit Committee and until March 2009, served as Chairman of the Nominating Committee. Mr. Berman's career spans over 35 years of venture capital, management and merger & acquisitions experience. In the last five years, he has served as a professional director and/or officer of about a dozen public and private companies. He is currently CEO of Nexmed, a small public biotech company, Chairman of National Investment Managers, a public company in pension administration and investment management, Chairman of Candidate Resources, a private company delivering HR services over the Web, and Chairman of Fortress Technology Systems (homeland security). In addition to serving as a director of NeoStem Mr. Berman also serves as a director of six other public companies: Broadcaster, Inc., NexMed, Inc., National Investment Managers, Inc., Advaxis, Inc., Superfly Advertising Inc. and Easylink Services International, Inc.
Pursuant to the terms of the Securities Purchase Agreement in the June 2006 private placement, the Company agreed to permit the lead investor, DCI Master LDC, to designate one additional independent member to the Company's Board of Directors reasonably acceptable to the Company. This right terminated in 2007. Mr. Berman was originally appointed to the Board of Directors in November 2006 to serve as such designee.
Drew Bernstein, CPA
In 1983 Mr. Bernstein cofounded Bernstein & Pinchuk LLP, an accounting firm, which is an independent member of the BDO Seidman Alliance, headquartered in New York. His early recognition of the global marketplace and his extensive work in the People's Republic of China resulted in the rapid expansion of his firm's services to that nation, where he has established local offices to better serve client needs. In addition, his experience in retail, manufacturing, hospitality, professional practices, and real estate has contributed to the growth of the firm's client base abroad. Mr. Bernstein is fluent in French and serves as an accountant and business advisor worldwide, providing specialized auditing and accounting services to public and non-public companies throughout the United States, China, Europe, and Africa.
Mr. Bernstein has been responsible for more than 200 real estate transactions with an aggregate value in excess of $3 billion. He also serves as director and chairman of the audit committee of AMEX- and OTCBB-listed companies. A frequent speaker at industry, investment banking and university conferences, he has also qualified as an expert witness. He is an active member of the board of directors and an officer of a prestigious foundation that was honored with the President's Voluntary Action Award by the late President Ronald Reagan.
Mr. Bernstein received his BS degree from the University of Maryland Business School. He is licensed in the state of New York and other states and is a member of the AICPA, the NYSSCPA and the NSA.
伯斯汀先生在1983年与他人共同创立了Bernstein & Pinchuk有限责任公司（B&P）。B&P是一家发展迅速的会计师事务所，BDO SEIDMAN 联盟的独立成员公司之一, 总部位于纽约。伯斯汀先生对于会计行业全球市场的认知以及他在中国广泛的游历促成了他到北京扩展公司服务的想法。在北京，他建立了一个合作办事处，从而更 好地为日益增长的客户需要提供服务。此外，他在零售制造业、酒店业、专业实践和房地产方面丰富的阅历为他带来了更多的客户。伯斯汀先生能讲一口流利法语， 为欧洲许多国家的客户提供过商业咨询和专业的审计服务，包括捷克、法国、斯洛文尼亚、德国、瑞士、和以色列的客户。
伯斯汀先生在全球的多家房地产 企业担任过会计师和顾问，迄今已经负责办理过200多宗交易，总价值超过30亿美元。同时他也是美国证券交易和场外柜台交易系统的独立董事和审计委员会主 席。
伯斯汀先生具有为证券交易委员会提供审计服务的资质，同时他还是一名专家见证人。他既是董事会活跃的成员，也是被已故前总统里根授予the President's Voluntary Action 奖的著名基金会的官员。
伯斯汀先生在马里兰大学商学院获得理学学位，持有包括纽约州 在内的多州的会计师执照，同时还是美国会计师协会、NYSSCPA和NSA的成员。
Edward C. Geehr, M.D., Director
Until 2009, Dr. Edward Geehr had served as Executive Vice President of Operations for Abraxis BioScience, in which capacity Dr. Geehr was responsible for global commercial operations. Prior to joining Abraxis in 2008, Dr. Geehr had served as President of Allez Spine, LLC in 2004, a developer, manufacturer and distributor of medical devices. Dr. Geehr was a co-founder and executive chairman of IPC-The Hospitalist Company which became a publicly traded company in 2008. Dr. Geehr received his undergraduate degree from Yale University and his medical degree from Duke University. He trained in Emergency Medicine at UCLA and subsequently obtained Board certification. Dr. Geehr is the author of many scientific articles and books and held a faculty appointment at the University of California, San Francisco School of Medicine.
Steven S. Myers, Director
Steven S. Myers joined the Board of Directors of the Company in November 2006 and serves on the Compensation Committee, Audit Committee and Nominating Committee. In March 2009, Mr. Myers became Chairman of the Nominating Committee. Mr. Myers is the founder, and until his retirement in March 2007 was the Chairman and CEO, of SM&A (Nasdaq:WINS), the world's leading provider of Competition Management Services. SM&A helps businesses win structured competitive procurements and design successful transitions from proposals to programs. Since 1982, SM&A has managed over 1,000 proposals worth more than $340 billion for its clients and has achieved an 85% win rate on awarded contracts. The company has also supported more than 140 programs with a better than 93% client-satisfaction rating. SM&A routinely supports clients such as Boeing, Lockheed Martin, Accenture, Raytheon, Northrop Grumman, Motorola, and other Fortune 500 companies.
Mr. Myers graduated from Stanford University with a B.S. in Mathematics and had a successful career in the aerospace and defense sector supporting DoD and NASA programs before founding SM&A. He has a strong technical background in systems engineering and program management. Mr. Myers is also founder, President and CEO of Dolphin Capital Holdings, Inc, which owns, operates and leases business jet aircraft and does private equity investing in innovative enterprises. A serial entrepreneur, Mr. Myers has spearheaded a number of business innovations in aerospace & defense and in business aviation. He is a highly accomplished aviator.
Mingsheng Shi, Director
Mingsheng Shi has been serving as chairman of the board of directors of CBH’s subsidiary, Suzhou Erye Pharmaceutical Limited Company (“Erye”), since 2003. Currently, Mr. Shi is also the chairman of EET. Before that, Mr. Shi served for five years as the assistant director of Suzhou No.4 Pharmaceutical Limited Company, and seven years as the deputy director of Suzhou No.4 Pharmaceutical Limited Company, and five years as the factory director of Suzhou No.2 Pharmaceutical Limited Company, the predecessor company of Erye. Mr. Shi has a bachelor degree in Economics & Management from the Party School of the CPC. Mr. Shi holds a professional title which is Senior Economist. As a veteran of the Chinese pharmaceuticals industry, Mr. Shi is expected to contribute to the industry knowledge of the board in terms of operational management, strategic growth and future acquisitions.
Eric Wei, Director
Eric Wei is one of the founders and the managing partner of RimAsia Capital Partners, L.P. Prior to establishing RimAsia in January of 2005, Mr. Wei was a managing director of Gilbert Global Equity Partners, a US$1.2 billion global private equity fund; a founding partner of Crimson Asia Capital Partners, a US$435 million Asian private equity program; a founder and investment committee member of the US$800 million Asian Infrastructure Fund, and an investor and director of The Asian MBO Fund. Mr. Wei has also previously been an investment banker with over 10 years of experience at Peregrine Capital, Prudential Securities, Lazard Freres and Citibank. Mr. Wei received a Bachelor of Science degree in Math and Economics from Amherst College and a Master of Business Administration degree from the Wharton Graduate School of Management at the University of Pennsylvania.
|
